Eureka’s ARTEMIS® CAR T Cells Show Breakthrough Potential in Solid Tumors in NCI-Led Study Published in Cell Reports Medicine

Excerpt from the Press Release:

EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled “Antibody–Gamma/Delta T Cell Receptors Targeting GPC2 Regress Neuroblastoma with Low Antigen Density” in Cell Reports Medicine. The study, led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, demonstrated that Eureka’s ARTEMIS^® CAR T cells significantly outperformed conventional CAR T cells in preclinical models of neuroblastoma, a high-risk pediatric solid tumor.

These findings mark a potential breakthrough in cell therapy, where conventional CAR T cells have struggled to show consistent success in solid tumors, and safety challenges have limited broader adoption across cancer types. This publication presents the first head-to-head comparison between Eureka’s ARTEMIS CAR T and conventional CAR T cells in solid tumors, demonstrating clear superiority of the ARTEMIS platform in efficacy, tumor infiltration, and persistence. Together, these results position Eureka’s ARTEMIS platform to extend the reach of CAR T therapy beyond blood cancers to solid tumors, the next frontier in cell therapy.

Key Findings from the Study:

1. 16-Fold Greater Tumor Infiltration. ARTEMIS CAR T cells made up 54% of T cells within tumors, compared to just 3% for conventional CAR T cells, representing a 16-fold increase that highlights their superior ability to penetrate solid tumors.
   
   
2. Durable Tumor Control in Low-Antigen-Density Tumors. In neuroblastoma mouse models with low GPC2 antigen expression, ARTEMIS CAR T cells led to complete tumor regression and 100% survival at week 7. Conventional CAR T cells using the same antigen binder achieved only 50% survival.

Click the button below to read the entire Press Release:

Continue Reading The Press Release